BIIB:NASDAQ
Biogen Inc
$224.51
0.00%
(0.00) 1D
Sep 3, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Mkt. cap
33.17B
Avg. vol.
870.67K
Volume
69.00
P/E ratio
39.76
52-wk high
$225.80
52-wk low
$135.39
EPS
$5.65
Beta
0.17
Shares outstanding
147.75M
No. of employees
8K
Mkt. cap
33.17B
Avg. vol.
870.67K
Volume
69.00
P/E ratio
39.76
52-wk high
$225.80
52-wk low
$135.39
EPS
$5.65
Beta
0.17
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
2 hours ago
Biogen stock gains after Piper Sandler lifts target to USD 245
Simply Wall Street
·
8 hours ago
Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention?
Stock Titan
·
13 hours ago
Up to 20% of children with Dravet syndrome die before adulthood. A long-term study of an experimental drug showed fewer severe seizures.
Stock Titan
·
16 hours ago
Biogen (BIIB) awards 7,405 stock units to its top lawyer
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com